Report post
FDA denies approval of neffy stock with 500% upside potential, surprising investors. ARS Pharmaceuticals' SPRY stock faces scrutiny in technical analysis review. Allergists and parents express disappointment over FDA's rejection of EpiPen alternative. Investors await FDA's next move in this volatile market.

The World's Leading Crypto Trading Platform

Get my welcome gifts